Article

Fellow eye study finds efficacy and benefits for photochromic IOL

Results from a study evaluating the first photochromic IOL (Aurium, Medennium) indicate that it provides stable and effective pseudophakic correction and outperforms a yellow IOL under mesopic conditions, said David Mendez Noble, MD, Mexicali, Mexico.

Results from a study evaluating the first photochromic IOL (Aurium, Medennium) indicate that it provides stable and effective pseudophakic correction and outperforms a yellow IOL under mesopic conditions, said David Mendez Noble, MD, Mexicali, Mexico.

The photochromic IOL responds to environmental changes so that it provides blue-blocking protection only as needed. Under conditions in which there is low ultraviolet (UV) light, the optic is clear and does not block blue light, but it changes quickly to yellow in the presence of UV light so that it is able to block the higher levels of blue light that are present in sunlight.

The performance of the photochromic IOL was investigated in a study enrolling 15 patients with the photochromic IOL implanted in one eye and a yellow aspherical IOL (AcrySof IQ [SN60WF], Alcon Laboratories) implanted in the fellow eye. Best-corrected visual acuity (BCVA) was measured indoors at various follow-up visits using Snellen charts with lighting conditions being increased over the range from 11 to 1,200 lux. BCVA also was checked at 30 days postoperatively outdoors, with and without sunglasses worn.

The BCVA results indicated the photochromic IOL was effective and provided vision that was stable through 2 years. In the indoor testing, BCVA increased with both IOLs as the illumination levels increased, but the photochromic IOL outperformed the aspherical IOL in low-level illumination conditions. In the outdoor testing, little difference was found between BCVA measured with and without sunglasses in the photochromic IOL eyes, whereas putting on sunglasses negatively impacted BCVA in 11 eyes with the aspherical IOL.

"Permanently yellow IOLs block 50% of blue light, but there is debate over whether such lenses have a negative impact on night vision, color vision, and the circadian cycle," Dr. Noble said. "The [photochromic IOL] is designed to provide all the benefits of a blue light-blocking IOL without any of the potential downsides."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.